Target Corp. Stock
€111.00
Your prediction
Target Corp. Stock
Pros and Cons of Target Corp. in the next few years
Pros
Cons
Performance of Target Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Target Corp. | -0.360% | 5.894% | 12.707% | 36.956% | 33.285% | -24.500% | -34.567% |
| Burlington Stores | -0.710% | 0.000% | 7.463% | 51.579% | 20.000% | 68.421% | 8.271% |
| TJX Companies Inc. | 0.370% | 1.119% | 0.773% | 22.314% | 1.742% | 89.882% | 135.325% |
| Dollar Tree Inc. | 0.320% | 1.934% | -6.115% | 18.851% | -16.910% | -36.031% | -8.357% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Target Corporation (TGT), a prominent player in the diversified retail industry, showcases a notable financial performance over the recent years. The company's financial statements indicate a steady growth in revenue, accompanied by improvements in various areas of their operations. Despite facing challenges in specific sectors, Target has demonstrated resilience and a strong ability to withstand market complexities.
Growth in Revenue: Target's financial data reveals consistent growth in its revenue streams. For instance, the company's total revenue increased from €93.56 billion in 2021 to $109.12 billion in 2023, marking a significant upswing within this timeframe.
Improvement in Gross Profit: The company experienced a rise in gross profit over the years, growing from €27.38 billion in 2021 to $26.89 billion in 2023. This growth is indicative of the company's ability to generate income while maintaining control over production costs.
Comments
News
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs):
OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual
3 Retail Stocks to Watch for a Post-Tax-Day Bump
The confluence of the start of earnings season and a boost to some wallets from tax refunds can make mid-April a time for share price bumps.
Traders looking for a short-term “refund effect” often
Vanguard Mining Corp. Files Maiden NI 43-101 Technical Report Highlighting Gold–Copper Porphyry–Epithermal Potential at the Brussels Creek Project, British Columbia
Vancouver, BC – April 10, 2026 – Vanguard Mining Corp. ("Vanguard" or the "Company") (UUU: CSE | UUUFF: OTCID | SL51: Frankfurt) is pleased to announce that it has filed its maiden